X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-14 | SPRB | Spruce Biosciences, Inc. | Novo Holdings A/s | 10% | S - Sale | $0.89 | -1,912,316 | 4,810,020 | -28% | -$1,698,902 | ||||||
2024-03-18 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale | $69.34 | -6,825 | 9,485 | -42% | -$473,255 | ||||||
D | 2024-03-15 | HRMY | Harmony Biosciences Holdings, Inc. | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | S - Sale+OE | $32.00 | -11,979 | 0 | -100% | -$383,328 | |||||
2024-03-15 | LFVN | Lifevantage Corp | Lewis Darwin | Dir | P - Purchase | $7.00 | +449 | 107,502 | 0% | +$3,142 | ||||||
D | 2024-03-15 | ACLX | Arcellx, Inc. | Ware Olivia C | Dir | S - Sale+OE | $70.40 | -9,000 | 0 | -100% | -$633,582 | |||||
2024-03-14 | APLT | Applied Therapeutics, Inc. | Shendelman Shoshana | Pres, CEO, 10% | S - Sale | $5.39 | -318,573 | 8,148,305 | -4% | -$1,717,108 | ||||||
2024-03-14 | APLT | Applied Therapeutics, Inc. | Perfetti Riccardo | Chief Medical Officer | S - Sale | $5.39 | -110,804 | 1,031,537 | -10% | -$597,234 | ||||||
2024-03-14 | APLT | Applied Therapeutics, Inc. | Hansard Adam | Chief Commercial Officer | S - Sale | $5.39 | -48,871 | 732,919 | -6% | -$263,415 | ||||||
M | 2024-03-14 | IMRX | Immuneering Corp | Cormorant Asset Management, LP | 10% | S - Sale | $3.02 | -909,091 | 3,295,273 | -22% | -$2,749,003 | |||||
2024-03-14 | APLT | Applied Therapeutics, Inc. | Funtleyder Leslie D. | CFO | S - Sale | $5.39 | -28,727 | 308,421 | -9% | -$154,839 | ||||||
2023-01-09 | MIRM | Mirum Pharmaceuticals, Inc. | Radovich Peter | Pres, COO | S - Sale | $20.62 | -1,379 | 33,316 | -4% | -$28,438 | ||||||
D | 2024-03-15 | CRSP | Crispr Therapeutics AG | Prasad Raju | CFO | S - Sale+OE | $72.69 | -3,524 | 6,476 | -35% | -$256,160 | |||||
D | 2024-03-15 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $72.48 | -20,000 | 408,122 | -5% | -$1,449,628 | |||||
2023-01-09 | MIRM | Mirum Pharmaceuticals, Inc. | Vig Pamela | Chief Scientific Officer | S - Sale | $20.62 | -1,379 | 102,312 | -1% | -$28,438 | ||||||
2019-09-10 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief Development Officer | P - Purchase | $10.64 | +965 | 104,369 | +1% | +$10,268 | ||||||
2023-01-09 | MIRM | Mirum Pharmaceuticals, Inc. | Longpre Lara | Chief Development Officer | S - Sale | $20.62 | -1,003 | 104,369 | -1% | -$20,684 | ||||||
2023-01-09 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale | $20.62 | -5,159 | 300,523 | -2% | -$106,390 | ||||||
2024-03-18 | MIRM | Mirum Pharmaceuticals, Inc. | Bjerkholt Eric | CFO | P - Purchase | $25.80 | +2,000 | 12,000 | +20% | +$51,600 | ||||||
D | 2024-03-14 | MAIA | Maia Biotechnology, Inc. | Chaouki Steven M | Dir | P - Purchase | $1.17 | +34,641 | 88,891 | +64% | +$40,530 | |||||
M | 2024-03-14 | RNAC | Cartesian Therapeutics, Inc. | Springer Timothy A | Dir, 10% | P - Purchase | $0.56 | +1,185,872 | 38,612,405 | +3% | +$666,222 | |||||
D | 2024-03-15 | CSWI | Csw Industrials, Inc. | Armes Joseph B | COB, Pres, CEO | S - Sale+OE | $230.06 | -1,000 | 51,497 | -2% | -$230,057 | |||||
D | 2024-03-14 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale+OE | $21.86 | -15,000 | 408,035 | -4% | -$327,942 | |||||
M | 2024-03-11 | UPXI | Upexi, Inc. | Marshall Allan | CEO, 10% | P - Purchase | $0.58 | +77,773 | 2,939,654 | +3% | +$44,739 | |||||
2024-03-18 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $0.87 | +500,000 | 244,164,353 | 0% | +$437,100 | ||||||
2024-03-18 | ZTS | Zoetis Inc. | Lagano Roxanne | EVP | S - Sale | $173.33 | -923 | 16,517 | -5% | -$159,984 | ||||||
2024-03-15 | APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP, Chief Accounting Officer | S - Sale | $56.46 | -184 | 38,883 | 0% | -$10,389 | ||||||
2024-03-14 | ALXO | Alx Oncology Holdings Inc | Lettmann Jason | CEO | P - Purchase | $11.31 | +4,400 | 171,620 | +3% | +$49,771 | ||||||
2024-03-14 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $34.60 | -93 | 81,363 | 0% | -$3,218 | ||||||
2024-03-18 | ALKS | Alkermes Plc. | Nichols Christian Todd | SVP, Chief Commercial Officer | S - Sale | $28.10 | -10,417 | 65,911 | -14% | -$292,740 | ||||||
2024-03-15 | AIM | Aim Immunotech Inc. | Appelrouth Stewart | Dir | P - Purchase | $0.33 | +90,910 | 239,765 | +61% | +$30,000 | ||||||
2024-03-15 | AIM | Aim Immunotech Inc. | Equels Thomas K | CEO, Pres | P - Purchase | $0.33 | +75,758 | 716,455 | +12% | +$25,000 | ||||||
2024-03-15 | AIM | Aim Immunotech Inc. | Rodino Peter W III | COO, Secretary, Gen. Counsel | P - Purchase | $0.33 | +37,879 | 181,718 | +26% | +$12,500 | ||||||
2024-03-14 | RZLT | Rezolute, Inc. | Roberts Brian Kenneth | Chief Medical Officer | P - Purchase | $1.88 | +10,000 | 53,128 | +23% | +$18,800 | ||||||
A | 2024-03-07 | RZLT | Rezolute, Inc. | Roberts Brian Kenneth | Chief Medical Officer | P - Purchase | $1.85 | +500 | 43,128 | +1% | +$925 | |||||
2024-03-15 | WLK | Westlake Corp | Buesinger Robert F. | EVP, HIP, IT, Digital | S - Sale | $144.50 | -3,878 | 21,144 | -15% | -$560,371 | ||||||
M | 2024-03-13 | ADMA | Adma Biologics, Inc. | Elms Steve | Dir | S - Sale | $6.11 | -1,038,284 | 2,653,828 | -28% | -$6,339,418 | |||||
DM | 2024-03-14 | AXSM | Axsome Therapeutics, Inc. | Jeffs Roger | Dir | S - Sale+OE | $69.84 | -32,323 | 167,668 | -16% | -$2,257,449 | |||||
2024-03-14 | ASRT | Assertio Holdings, Inc. | Tyree James L | Dir | S - Sale | $1.12 | -10,251 | 188,251 | -5% | -$11,463 | ||||||
M | 2024-03-13 | IGMS | Igm Biosciences, Inc. | Weber Steven | Principal Accounting Officer | S - Sale | $10.01 | -993 | 26,507 | -4% | -$9,943 | |||||
M | 2024-03-13 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.14 | -100,000 | 12,846,116 | -1% | -$913,681 | |||||
M | 2024-03-13 | IGMS | Igm Biosciences, Inc. | Takimoto Chris H | Chief Medical Officer | S - Sale | $10.01 | -5,424 | 94,388 | -5% | -$54,312 | |||||
M | 2024-03-13 | IGMS | Igm Biosciences, Inc. | Tahir Misbah | CFO | S - Sale | $10.01 | -5,440 | 90,418 | -6% | -$54,472 | |||||
M | 2024-03-13 | SPRY | Ars Pharmaceuticals, Inc. | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.14 | -100,000 | 12,846,116 | -1% | -$913,681 | |||||
M | 2024-03-13 | IGMS | Igm Biosciences, Inc. | Schwarzer Fred | CEO, Pres | S - Sale | $10.01 | -8,947 | 413,369 | -2% | -$89,588 | |||||
M | 2024-03-13 | IGMS | Igm Biosciences, Inc. | Keyt Bruce | Chief Scientific Officer | S - Sale | $10.01 | -3,945 | 175,895 | -2% | -$39,502 | |||||
M | 2024-03-13 | IGMS | Igm Biosciences, Inc. | Decker Lisa Lynn | Chief Business Officer | S - Sale | $10.01 | -3,376 | 61,006 | -5% | -$33,805 | |||||
M | 2024-03-14 | KYMR | Kymera Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $40.25 | -127,543 | 806,697 | -14% | -$5,133,263 | |||||
A | 2024-01-10 | FOLD | Amicus Therapeutics, Inc. | Crowley John F | Exec COB | S - Sale | $13.65 | -31,614 | 927,013 | -3% | -$431,452 | |||||
D | 2024-03-14 | MAIA | Maia Biotechnology, Inc. | Smith Stan | Dir | P - Purchase | $1.17 | +170,940 | 857,568 | +25% | +$200,000 | |||||
D | 2024-03-14 | MAIA | Maia Biotechnology, Inc. | Louie Ngar Yee | Dir | P - Purchase | $1.17 | +170,940 | 1,147,524 | +18% | +$200,000 | |||||
D | 2024-03-14 | MAIA | Maia Biotechnology, Inc. | Luput Cristian | Dir | P - Purchase | $1.17 | +69,282 | 367,350 | +23% | +$81,060 | |||||
D | 2024-03-14 | MAIA | Maia Biotechnology, Inc. | Guerrero Ramiro | Dir | P - Purchase | $1.17 | +6,928 | 319,600 | +2% | +$8,106 | |||||
2024-03-13 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $108.54 | -15,000 | 11,797,969 | 0% | -$1,628,031 | ||||||
D | 2024-03-13 | SUPN | Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P. | SVP of IP, CSO | S - Sale+OE | $33.74 | -62,366 | 8,570 | -88% | -$2,104,289 | |||||
2024-03-13 | CSWI | Csw Industrials, Inc. | Sullivan Don | EVP, GM Contractor Solutions | S - Sale | $230.90 | -7,826 | 28,956 | -21% | -$1,807,032 | ||||||
2024-03-13 | VTRS | Viatris Inc | Mauro Anthony | See Remarks | S - Sale | $12.09 | -250,000 | 248,618 | -50% | -$3,023,700 | ||||||
D | 2024-03-14 | NBIX | Neurocrine Biosciences Inc | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $139.38 | -75,000 | 40,778 | -65% | -$10,453,418 | |||||
D | 2024-03-13 | NBIX | Neurocrine Biosciences Inc | Pops Richard F | Dir | S - Sale+OE | $140.33 | -23,200 | 29,512 | -44% | -$3,255,621 | |||||
D | 2024-03-13 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $140.14 | -3,000 | 7,507 | -29% | -$420,419 | |||||
2024-03-13 | BPMC | Blueprint Medicines Corp | Lee Philina | CHIEF COMMERCIAL OFFICER | S - Sale | $90.40 | -8,023 | 34,729 | -19% | -$725,277 | ||||||
2024-03-13 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale | $28.33 | -723 | 77,692 | -1% | -$20,483 | ||||||
2024-03-13 | AKRO | Akero Therapeutics, Inc. | White William Richard | CFO | S - Sale | $28.33 | -724 | 49,630 | -1% | -$20,511 | ||||||
2024-03-13 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Pres, CEO | S - Sale | $28.33 | -1,969 | 589,447 | 0% | -$55,782 | ||||||
2024-03-13 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | COO | S - Sale | $28.33 | -651 | 328,306 | 0% | -$18,443 | ||||||
2024-03-13 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale | $28.33 | -619 | 182,558 | 0% | -$17,536 | ||||||
2024-03-13 | TGTX | Tg Therapeutics, Inc. | Lonial Sagar | Dir | S - Sale | $15.94 | -5,000 | 108,878 | -4% | -$79,675 | ||||||
DM | 2024-03-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $240.31 | -30,000 | 130 | -100% | -$7,209,192 | |||||
2024-03-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Chief Accounting Officer | S - Sale | $60.48 | -341 | 63,204 | -1% | -$20,624 | ||||||
2024-03-14 | CF | Cf Industries Holdings, Inc. | Hoker Richard A | VP, Corporate Controller | S - Sale | $84.11 | -11,029 | 54,416 | -17% | -$927,612 | ||||||
M | 2024-03-14 | CE | Celanese Corp | Richardson Scott A | EVP, COO | S - Sale | $156.67 | -4,000 | 75,012 | -5% | -$626,680 | |||||
2024-03-14 | CE | Celanese Corp | Kelly Thomas Francis | SVP, EM | P - Purchase | $156.70 | +1,400 | 57,023 | +3% | +$219,373 | ||||||
2024-03-13 | SKYE | Skye Bioscience, Inc. | 5Am Partners Vii, LLC | 10% | P - Purchase | $10.00 | +450,000 | 10,179,505 | +5% | +$4,500,000 | ||||||
D | 2024-03-13 | RNA | Avidity Biosciences, Inc. | Maclean Michael F | CFO | S - Sale+OE | $24.52 | -40,000 | 44,093 | -48% | -$980,760 | |||||
DM | 2024-03-13 | VCEL | Vericel Corp | Colangelo Dominick | Pres, CEO | S - Sale+OE | $44.35 | -35,000 | 194,870 | -15% | -$1,552,075 | |||||
A | 2024-03-08 | VCEL | Vericel Corp | Flynn Sean C. | SVP, GC | S - Sale | $45.33 | -8,115 | 167 | -98% | -$367,853 | |||||
D | 2024-03-14 | REGN | Regeneron Pharmaceuticals, Inc. | Murphy Andrew J | EVP Research | S - Sale+OE | $956.47 | -5,783 | 52,616 | -10% | -$5,531,290 | |||||
2024-03-15 | ANIX | Anixa Biosciences Inc | Baskies Arnold M | Dir | P - Purchase | $3.63 | +10,000 | 110,000 | +10% | +$36,300 | ||||||
2024-03-15 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $3.22 | +30,000 | 491,925 | +6% | +$96,600 | ||||||
M | 2024-03-12 | CMPS | Compass Pathways Plc | Goldsmith George Jay | Dir, 10% | S - Sale | $10.70 | -65,886 | 8,121,534 | -1% | -$704,821 | |||||
M | 2024-03-12 | CMPS | Compass Pathways Plc | Malievskaia Ekaterina | Dir, 10% | S - Sale | $10.70 | -65,886 | 8,121,534 | -1% | -$704,821 | |||||
2024-03-14 | XERS | Xeris Biopharma Holdings, Inc. | Schmid John P. | Dir | P - Purchase | $2.16 | +4,500 | 74,159 | +6% | +$9,720 | ||||||
D | 2024-03-13 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | SrVP, CFO, Prin Fin, Acct Ofcr | P - Purchase | $7.29 | +1,010 | 15,503 | +7% | +$7,363 | |||||
D | 2024-03-13 | APRE | Aprea Therapeutics, Inc. | Seizinger Bernd R. | Dir | P - Purchase | $7.29 | +6,860 | 33,685 | +26% | +$50,009 | |||||
D | 2024-03-13 | APRE | Aprea Therapeutics, Inc. | Henneman John B III | Dir | P - Purchase | $7.29 | +6,860 | 8,139 | +536% | +$50,009 | |||||
D | 2024-03-13 | APRE | Aprea Therapeutics, Inc. | Gilad Oren | Pres, CEO | P - Purchase | $7.29 | +2,000 | 324,770 | +1% | +$14,580 | |||||
DM | 2024-03-12 | RXRX | Recursion Pharmaceuticals, Inc. | Secora Michael | CFO | S - Sale+OE | $10.74 | -50,000 | 1,204,179 | -4% | -$537,190 | |||||
DM | 2024-03-12 | AVTE | Aerovate Therapeutics, Inc. | Eldridge George A | SEE REMARKS | S - Sale+OE | $25.03 | -4,067 | 1,960 | -67% | -$101,815 | |||||
M | 2024-03-12 | BGNE | Beigene, Ltd. | Oyler John | CEO | S - Sale | $167.36 | -50,000 | 48,162,317 | 0% | -$8,368,017 | |||||
2022-12-29 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | Senanayake Chris | Dir | S - Sale | $1.61 | -1,626 | 2,791 | -37% | -$2,610 | ||||||
2024-03-14 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $0.89 | +500,000 | 243,664,353 | 0% | +$444,300 | ||||||
D | 2024-03-12 | SUPN | Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P. | SVP of IP, CSO | S - Sale+OE | $32.99 | -3,884 | 8,570 | -31% | -$128,133 | |||||
2024-03-14 | CGTX | Cognition Therapeutics Inc | Ricciardi Lisa | CEO, Pres | P - Purchase | $1.75 | +5,700 | 291,345 | +2% | +$9,975 | ||||||
2024-03-13 | APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | S - Sale | $57.56 | -11,220 | 56,287 | -17% | -$645,838 | ||||||
D | 2024-03-12 | LYB | Lyondellbasell Industries N.V. | McMurray Michael C. | EVP, CFO | S - Sale+OE | $100.84 | -16,940 | 88,858 | -16% | -$1,708,219 | |||||
2024-03-13 | DD | Dupont De Nemours, Inc. | Goss Michael G. | Controller | S - Sale | $72.80 | -2,354 | 15,587 | -13% | -$171,371 | ||||||
DM | 2024-03-04 | LNZA | Lanzatech Global, Inc. | Burton Freya | Chief Sustainability Officer | S - Sale+OE | $3.20 | -87,493 | 49,846 | -64% | -$280,123 | |||||
2024-03-13 | WLK | Westlake Corp | Buesinger Robert F. | EVP, HIP, IT, Digital | S - Sale | $144.50 | -122 | 25,022 | 0% | -$17,629 | ||||||
M | 2022-07-22 | RZLT | Rezolute, Inc. | Kim Young-Jin | Dir | P - Purchase | $3.20 | +115,450 | 6,058,067 | +2% | +$369,858 | |||||
D | 2024-03-13 | CHD | Church & Dwight Co Inc /de/ | Bruno Barry A. | EVP, Chf Mktng Offcr Pres CD | S - Sale+OE | $104.55 | -9,926 | 7,228 | -58% | -$1,037,805 | |||||
2024-03-13 | CRMD | Cormedix Inc. | Todisco Joseph | CEO | P - Purchase | $3.74 | +13,561 | 352,839 | +4% | +$50,718 |
A | Amended filing |
D | Derivative transaction in filing (usually option exercise) |
E | Error detected in filing |
M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
S - Sale | Sale of securities on an exchange or to another person |
S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
P - Purchase | Purchase of securities on an exchange or from another person |